BMO raises Israel Chemicals stock price target on potash outlook By Investing.com

BMO Capital raised its price target on Israel Chemicals (ICL) to $6.50 from $6.00 and lifted its 2026 EBITDA forecast by about $100 million, now expecting results in the upper half of the company's revised $1.5 billion to $1.7 billion guidance range. The upgrade reflects improved potash pricing and margins, with smaller contributions from bromine and industrial products. Separately, ICL announced a CFO change effective June 15, 2026, with Asaf Alperovitz replacing retiring CFO Aviram Lahav.

Analysis

This is a modestly constructive read-through for ICL, but the more important signal is that the earnings revision is being driven by pricing/margin recovery rather than volume growth. That matters because it implies operating leverage is still available into a better potash tape, while the incremental contribution from bromine and industrial products suggests the rebound is broadening rather than being a one-factor story. In other words, the company is getting some cyclical help, but the real question is whether this is the early part of a multi-quarter margin repair or just a temporary normalization.

The second-order effect is on the fertilizer and specialty chemicals ecosystem: if potash pricing is firm enough to pull estimates meaningfully higher, smaller/global peers with less integrated cost structures should see the biggest relative EBIT uplift. That creates a potential long-the-quality-producer / short-the-least-pricily-discounted-peer dynamic, especially if the market starts pricing in a more durable cash generation cycle rather than a one-quarter beat. The CFO transition is not a catalyst by itself, but it does create an execution-risk window where capital allocation, hedging, and guidance credibility become more important than headline EBITDA.

The contrarian risk is that the market may already be anchoring on a cyclical upswing in fertilizers and underappreciating how quickly potash margins can mean-revert if supply discipline cracks or demand softens. At roughly 6x forward EV/EBITDA, the stock is not expensive, but it also is not distressed; that limits multiple expansion unless management can prove the higher earnings are sustainable beyond 2026. Over the next 1-3 months the key watch item is whether peer commentary confirms pricing strength; over 6-12 months the real driver will be whether this turns into free cash flow conversion and not just revised sell-side models.

Key Decisions for Investors

• Buy ICL on pullbacks over the next 2-4 weeks, targeting a 6-12 month hold; use the improved earnings trajectory as a catalyst, but size modestly because the valuation already reflects some recovery and upside is likely more EPS-driven than multiple-driven.
• Pair trade: long ICL / short a more operationally leveraged fertilizer or commodity chemical peer with weaker balance sheet quality over 3-6 months; the thesis is that ICL’s margin recovery is becoming more visible while weaker names are more vulnerable if pricing stabilizes but does not re-accelerate.
• Sell out-of-the-money puts on ICL into any post-news strength for 1-3 month tenor; implied downside should be cushioned by the revised estimates, and the position monetizes the market’s tendency to overpay for moderate cyclicals during expectation resets.
• For event-driven accounts, wait for the new CFO’s first capital allocation commentary before adding aggressively; if the June transition comes with more shareholder-return discipline or better hedge disclosure, the stock can rerate another 5-10% over the subsequent quarter.
• If potash price indicators roll over for 4-6 consecutive weeks, trim longs quickly; the name is still levered to cyclical pricing, so the risk/reward deteriorates fast if the margin story stops improving.